Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
73 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Inovio Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Inovio Pharmaceuticals, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Inovio Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Inovio Pharmaceuticals, Inc. - The report provides overview of Inovio Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Inovio Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Inovio Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Inovio Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Inovio Pharmaceuticals, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Inovio Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Inovio Pharmaceuticals, Inc. Snapshot 7 Inovio Pharmaceuticals, Inc. Overview 7 Key Information 7 Key Facts 7 Inovio Pharmaceuticals, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Inovio Pharmaceuticals, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 Inovio Pharmaceuticals, Inc. - Pipeline Products Glance 17 Inovio Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 Inovio Pharmaceuticals, Inc. - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Inovio Pharmaceuticals, Inc. - Drug Profiles 20 VGX-3100 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 INO-8000 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 FVH-1 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 influenza [strain A/H3N2] vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 INO-1400 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 INO-3106 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 INO-3510 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 INO-4212 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 INO-4500 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 INO-5150 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PENNVAX-B 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 PENNVAX-G 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PENNVAX-GP 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 VGX-3400X 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 VRC-01 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 chikungunya vaccine 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Clostridium difficile vaccine 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 dengue [serotypes 1, 2, 3, 4] (tetravalent) vaccine 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Gene Therapy for Ebola Virus Infections 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 influenza [strain A/H7N9] vaccine 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 INO-5400 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 MAV-12 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Monoclonal Antibodies to Inhibit Tyrosinase for Oncology and Immunology 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Monoclonal Antibody for Chikungunya 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 respiratory syncytial virus vaccine 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 RSQ-15 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Vaccine for Cancer 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Vaccines for Neurological Disorders 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Inovio Pharmaceuticals, Inc. - Pipeline Analysis 51 Inovio Pharmaceuticals, Inc. - Pipeline Products by Target 51 Inovio Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 53 Inovio Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 54 Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 55 Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates 56 Inovio Pharmaceuticals, Inc. - Dormant Projects 66 Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products 67 Discontinued Pipeline Product Profiles 67 mifepristone 67 VGX-410C 67 Inovio Pharmaceuticals, Inc. - Company Statement 68 Inovio Pharmaceuticals, Inc. - Locations And Subsidiaries 71 Head Office 71 Other Locations & Subsidiaries 71 Appendix 72 Methodology 72 Coverage 72 Secondary Research 72 Primary Research 72 Expert Panel Validation 72 Contact Us 72 Disclaimer 73
List of Tables
Inovio Pharmaceuticals, Inc., Key Information 7 Inovio Pharmaceuticals, Inc., Key Facts 7 Inovio Pharmaceuticals, Inc. - Pipeline by Indication, 2016 9 Inovio Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 11 Inovio Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 12 Inovio Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016 13 Inovio Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 14 Inovio Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016 15 Inovio Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 16 Inovio Pharmaceuticals, Inc. - Phase II, 2016 17 Inovio Pharmaceuticals, Inc. - Phase I, 2016 18 Inovio Pharmaceuticals, Inc. - Preclinical, 2016 19 Inovio Pharmaceuticals, Inc. - Pipeline by Target, 2016 52 Inovio Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 53 Inovio Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 54 Inovio Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 55 Inovio Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 56 Inovio Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 66 Inovio Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 67 Inovio Pharmaceuticals, Inc., Subsidiaries 71
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.